Literature DB >> 25510910

Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin A on the energy metabolism of breast cancer cells.

Mariana Figueiredo Rodrigues1, Érika Carvalho, Paula Pezzuto, Franklin David Rumjanek, Nivea Dias Amoêdo.   

Abstract

Tumor cells display different bioenergetic profiles when compared to normal cells. In the present work we showed metabolic reprogramming by means of inhibitors of histone deacetylase (HDACis), sodium butyrate and trichostatin A in breast cancer cells representing different stages of aggressiveness and metabolic profile. When testing the effect of NaB and TSA on viability of cells, it was shown that non-tumorigenic MCF-10A cells were less affected by increasing doses of the drugs than the tumorigenic, hormone dependent, tightly cohesive MCF-7, T-47D and the highly metastatic triple-negative MDA-MB 231 cells. T-47D cells were the most sensitive to treatment with both, NaB and TSA. Experiments measuring anchorage- independent growth of tumor cells showed that MCF-7, T-47D, and MDA-MB-231 cells were equally sensitive to the treatment with NaB. The NaB induced an attenuation of glycolysis, reflected by a decrease in lactate release in MCF-7 and T47D lines. Pyruvate kinase activity was significantly enhanced by NaB in MDA-MB-231 cells only. In contrast, the inhibitor enhanced lactate dehydrogenase activity specifically in T-47 D cells. Glucose-6-phosphate dehydrogenase activity was shown to be differentially modulated by NaB in the cell lines investigated: the enzyme was inhibited in MCF-7 cells, whereas in T-47D and MDA-MB-231 cells, G6PDH was activated. NaB and TSA were able to significantly increase the oxygen consumption by MDA-MB-231 and T-47D cells. Collectively the results show that epigenetic changes associated to acetylation of proteins in general affect the energy metabolism in all cancer cell lines and that mitochondria may occupy a central role in metastasis.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  BREAST CANCER; MITOCHONDRIAL PHYSIOLOGY; SODIUM BUTYRATE; TRICHOSTATIN A

Mesh:

Substances:

Year:  2015        PMID: 25510910     DOI: 10.1002/jcb.25036

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  20 in total

Review 1.  Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Emmanouil Kalampokas; Theodoros Kalampokas; Eleftherios Spartalis; Afrodite Daskalopoulou; Serena Valsami; Michael Kontos; Afroditi Nonni; Konstantinos Kontzoglou; Despina Perrea; Nikolaos Nikiteas; Dimitrios Dimitroulis
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

2.  Involvement of 15-lipoxygenase-1 in the regulation of breast cancer cell death induced by sodium butyrate.

Authors:  Vahid Salimi; Mohammad Shabani; Mitra Nourbakhsh; Masoumeh Tavakoli-Yaraki
Journal:  Cytotechnology       Date:  2016-05-12       Impact factor: 2.058

3.  Sodium butyrate protects against oxidative stress in HepG2 cells through modulating Nrf2 pathway and mitochondrial function.

Authors:  Xingan Xing; Zheshu Jiang; Xue Tang; Panpan Wang; Yingrui Li; Yongjuan Sun; Guowei Le; Sixiang Zou
Journal:  J Physiol Biochem       Date:  2017-06-10       Impact factor: 4.158

4.  Short chain fatty acids exhibit selective estrogen receptor downregulator (SERD) activity in breast cancer.

Authors:  Abigail Schoeller; Keshav Karki; Arul Jayaraman; Robert S Chapkin; Stephen Safe
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

5.  A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.

Authors:  Takuya Sakamoto; Shogo Kobayashi; Daisaku Yamada; Hiroaki Nagano; Akira Tomokuni; Yoshito Tomimaru; Takehiro Noda; Kunihito Gotoh; Tadafumi Asaoka; Hiroshi Wada; Koichi Kawamoto; Shigeru Marubashi; Hidetoshi Eguchi; Yuichiro Doki; Masaki Mori
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

6.  Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment.

Authors:  Vahid Salimi; Zahra Shahsavari; Banafsheh Safizadeh; Ameinh Hosseini; Narges Khademian; Masoumeh Tavakoli-Yaraki
Journal:  Lipids Health Dis       Date:  2017-11-02       Impact factor: 3.876

Review 7.  Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches.

Authors:  C C Wong; Y Qian; J Yu
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

8.  Sodium butyrate has context-dependent actions on dipeptidyl peptidase-4 and other metabolic parameters.

Authors:  Eun-Sol Lee; Dong-Sung Lee; Prakash Raj Pandeya; Youn-Chul Kim; Dae-Gil Kang; Ho-Sub Lee; Byung-Chul Oh; Dae Ho Lee
Journal:  Korean J Physiol Pharmacol       Date:  2017-08-22       Impact factor: 2.016

9.  Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism.

Authors:  Shannon Rose; Sirish C Bennuri; Jakeira E Davis; Rebecca Wynne; John C Slattery; Marie Tippett; Leanna Delhey; Stephan Melnyk; Stephen G Kahler; Derrick F MacFabe; Richard E Frye
Journal:  Transl Psychiatry       Date:  2018-02-02       Impact factor: 6.222

10.  Characterization of inorganic phosphate transport in the triple-negative breast cancer cell line, MDA-MB-231.

Authors:  Thais Russo-Abrahão; Marco Antônio Lacerda-Abreu; Tainá Gomes; Daniela Cosentino-Gomes; Ayra Diandra Carvalho-de-Araújo; Mariana Figueiredo Rodrigues; Ana Carolina Leal de Oliveira; Franklin David Rumjanek; Robson de Queiroz Monteiro; José Roberto Meyer-Fernandes
Journal:  PLoS One       Date:  2018-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.